drugset / Trial / NCT02708680
Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the safety and tolerability of entinostat used in combination with atezolizumab in participants with Advanced Triple Negative Breast Cancer (aTNBC). Additionally, the purpose of the study is to assess how effective entinostat and atezolizumab are in combination in participants with aTNBC.
Timeline
- Start
- 2016-05
- Primary completion
- 2021-03-31
- Completion
- 2021-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Comparator | Entinostat | Small molecule | 2 mg | Oral |
| Comparator | Entinostat | Small molecule | 3 mg | Oral |
| Comparator | Entinostat | Small molecule | 5 mg | Oral |